MedTrace Logo

Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis

NCT00689520 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 241

Last updated 2008-06-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether low-molecular-weight heparin could be equally or more effective than oral anticoagulation in the long-term treatment of deep venous thrombosis.

Conditions

  • Venous Thromboembolism

Interventions

DRUG

tinzaparin

tinzaparin (Innohep®) subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months

DRUG

acenocoumarol

tinzaparin subcutaneously 175 IU anti-Xa/kg of body weight once daily for 7 days followed by acenocoumarol for 6 months

Sponsors & Collaborators

  • LEO Pharma

    collaborator INDUSTRY

  • Hospital Universitari de Bellvitge

    lead OTHER

Principal Investigators

  • Antoni Romera, MD · Hospital Universitari de Bellvitge

  • Antoni Romera, MD · Hospital Universitari de Bellvitge

  • Oriol Lapiedra, MD · Hospital Creu Roja de l'Hospitalet

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Primary Completion
2005-01-31
Completion
2005-01-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00689520 on ClinicalTrials.gov